Moreover, downregulating the rate-limiting enzymes of serine/glycine metabolism, such as phosphoserine phosphatase (PSPH) and phosphoserine aminotransferase 1 (PSAT1), may disrupt the pro-tumor effects mediated by serine/glycine metabolism (7, 75). The gene discussed is PSAT1; the disease is neoplasm.